Bausch + Lomb, an eye health products company, completed the acquisition of AcuFocus, an ophthalmic medical device company. Financial terms were not disclosed. “Cataracts are the largest contributor to global blindness in adults aged 50 years and older, with more than 15m individuals, or approximately 45% of the more than 33m cases of global blindness.5 We believe that the IC-8 Apthera EDOF IOL will bolster our surgical portfolio by enhancing our IOL offerings, which is a strategic area of focus for Bausch + Lomb. We will continue to focus on areas of unmet medical need that we believe will help drive long-term growth in our core segments, and importantly, help us achieve our mission of helping people see better to live better,” Joseph C. Papa, Bausch + Lomb CEO.